Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

Van Goor F, Straley KS, Cao D, González J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P.

Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1117-30. Epub 2006 Jan 27.

PMID:
16443646
2.

Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function.

Stanton BA.

Wien Klin Wochenschr. 1997 Jun 27;109(12-13):457-64. Review.

PMID:
9261986
3.
4.

CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.

Verkman AS, Lukacs GL, Galietta LJ.

Curr Pharm Des. 2006;12(18):2235-47. Review.

PMID:
16787252
5.

Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery.

Eidelman O, Zhang J, Srivastava M, Pollard HB.

Am J Pharmacogenomics. 2001;1(3):223-38. Review.

PMID:
12083969
6.
7.

Pharmacological treatment of the ion transport defect in cystic fibrosis.

Roomans GM.

Expert Opin Investig Drugs. 2001 Jan;10(1):1-19. Review.

PMID:
11116277
8.

Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.

Roomans GM.

Am J Respir Med. 2003;2(5):413-31. Review.

PMID:
14719993
9.

Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?

Valle CW, Vij N.

Curr Mol Med. 2012 Aug;12(7):860-71. Review.

PMID:
22697346
10.

On the discovery and development of CFTR chloride channel activators.

Becq F.

Curr Pharm Des. 2006;12(4):471-84. Review.

PMID:
16472140
11.

Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.

Kim Chiaw P, Eckford PD, Bear CE.

Essays Biochem. 2011 Sep 7;50(1):233-48. doi: 10.1042/bse0500233. Review.

PMID:
21967060
12.

[Early bronchial inflammation in cystic fibrosis].

Puchelle E.

J Soc Biol. 2002;196(1):29-35. Review. French.

PMID:
12134630
13.

Molecular biology of cystic fibrosis.

Drumm ML, Collins FS.

Mol Genet Med. 1993;3:33-68. Review.

PMID:
7693108
14.

[Cystic fibrosis: molecular update and clinical implications].

Orozco L, Chávez M, Saldaña Y, Velázquez R, Carnevale A, González-del Angel A, Jiménez S.

Rev Invest Clin. 2006 Mar-Apr;58(2):139-52. Review. Spanish.

PMID:
16827266
15.

New horizons in the treatment of cystic fibrosis.

Cuthbert AW.

Br J Pharmacol. 2011 May;163(1):173-83. doi: 10.1111/j.1476-5381.2010.01137.x. Review.

16.

Emerging drug treatments for cystic fibrosis.

Zeitlin PL.

Expert Opin Emerg Drugs. 2003 Nov;8(2):523-35. Review.

PMID:
14662004
17.

[CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].

Becq F.

Arch Pediatr. 2003 Sep;10 Suppl 2:325s-332s. Review. French.

PMID:
14671929
18.

Cystic fibrosis and related diseases of the pancreas.

Naruse S, Kitagawa M, Ishiguro H, Fujiki K, Hayakawa T.

Best Pract Res Clin Gastroenterol. 2002 Jun;16(3):511-26. Review.

PMID:
12079272
19.

[Physiopathology of cystic fibrosis lung disease].

Chinet T.

Rev Mal Respir. 1999 Jun;16(3):339-45. Review. French.

PMID:
10472642
20.

[Genetics and cellular biology of cystic fibrosis].

Chinet T, Blouquit S.

Rev Prat. 2003 Jan 15;53(2):130-4. Review. French.

PMID:
12664842

Supplemental Content

Support Center